Scientists have developed a vaccine that might be able to prevent the flu virus from infecting a human in the spring of 2019.
The vaccine, developed by a team of researchers at Johns Hopkins University and the University of Texas Health Science Center at Houston, could be tested for effectiveness by spring of 2020.
The team has already developed the vaccine in an effort to combat the pandemic, but they’re now working to increase its efficacy in a real-world setting.
The research is being presented today at the annual meeting of the American Society for Microbiology in Chicago.
“It’s a big milestone, and it’s a milestone for us,” said study leader Dr. Jeffrey D. Burdick, professor of biomedical sciences and director of the Center for the Transmission of Microbial Infections at the Hopkins School of Medicine.
“The goal is to be able in the future to use the vaccine to make sure it works in a lab environment.”
The team has developed the first flu vaccine to prevent flu infection in humans in the early stages of the pandemics, a stage called early phase infection (EOSI).
Burdrick said the EOSI stage was especially important because the virus had already spread through human-to-human transmission, and there wasn’t much time left to stop the virus before it could infect a human.
“We have a much longer window to control the virus,” he said.
But we think it has the potential to work at the EoSI stage.””
This vaccine, which we have in clinical trials, is about a year old and is in Phase 2.
But we think it has the potential to work at the EoSI stage.”
The researchers developed a strain of influenza virus that was designed to replicate with a host’s immune system, called an influenza strain A. The new vaccine consists of two parts, one that is designed to target viruses with the EosI stage of the flu, and the other that targets viruses with EOSII.
This type of vaccine, known as a combination vaccine, targets a virus with a different set of mutations, or mutations that can affect its ability to infect the human host.
Burden of illness is decreased by about half the dose, Burdicks said.
“This vaccine is designed specifically for humans,” Burds said.
He said the vaccine could be administered to children, but he could not disclose how much cost.
“It’s designed to work in a very large population, but it is a safe and effective vaccine,” he added.
The vaccine is the work of researchers led by researchers from Johns Hopkins, the University at Buffalo and the UT Health Science Centre.
Bredrick said he was particularly proud of the work that was done by UT Health scientist Dr. Daniel Siegel, who developed the influenza virus vaccine in collaboration with Burdack.
“They’ve done a tremendous amount of work to come up with a vaccine,” Breds said of the researchers at UT Health.
The researchers say their work shows the vaccine is safe and that they have demonstrated efficacy in humans.
“The vaccine works in humans,” said Siegel.
“That’s really what we were excited about.
We had a very good test.
We’ve shown it works.
We can say it’s safe.
We have very good data showing it’s effective in humans.”
In the study, the team tested the vaccine against two viruses with different mutations, EosII and EosV.
The two viruses, EOSV and EOS, were found to be highly effective at preventing infection in mice and dogs, and in humans, who were tested for the vaccine and also vaccinated.
Bhedrick said that the researchers did not see any effect of the vaccine on the immune system of humans.
The results, he said, showed that there was no increase in the risk of illness or death associated with the vaccine.
“What this study has shown is that the vaccine works,” Bhedick said.
And, he added, “we think it will be safe in humans and that it will have an impact on our ability to control this pandemic.”